Showing 701-710 of 3545 results for "".
DermWireTV: Opzelura for Vitiligo; Biosimilars Boom; Updates from BTL and Cynosure; DIS Launch
https://practicaldermatology.com/topics/psoriasis/dermwiretv-opzelura-for-vitiligo-biosimilars-boom-updates-from-btl-and-cynosure-dis-launch/20109/FDA has approved Opzelura (ruxolitinib cream 1.5%, Incyte) for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older. Analysts predict that use of biosimilars in the US is about to increase significantly as Humira (adalimumab, AbbVie) faces patent eAn Update on AD Treatments for Pediatric Patients
https://practicaldermatology.com/topics/atopic-dermatitis/an-update-on-ad-treatments-for-pediatric-patients/23744/The therapeutic toolbox is expanding.Emerging Vitiligo Therapies
https://practicaldermatology.com/conferences/maui-derm-2022/emerging-vitiligo-therapies/20047/It’s really an exciting time to be treating vitiligo, says John E. Harris, MD, PhD. He reviews Phase 2 and 3 clinical trials for ruxolitinib, a topical JAK inhibitor, and the hope that the FDA could soon approve it for the treatment of vitiligo. He also discusses other possible targeted treatments iManaging Advanced Skin Cancers
https://practicaldermatology.com/conferences/aad-2021/managing-advanced-skin-cancers/19920/Treatment of advanced NMSC can be a challenge, but therapeutic options continue to expand. Todd Schlesinger, MD discusses real-world use of hedgehog inhibitors—including modified regimens and adjuvant use—and PD-1 inhibitors for advanced disease.Eye Opener
https://practicaldermatology.com/programs/practical-dermatology/eye-opener/19918/From each individual's implicit bias to the systemic bias that influences the tools of research and clinical practice, innumerable factors go into every patient encounter. Only individuals who are open to recognizing and confronting bias can overcome it. Panelists share their personal perspectives oBackdoor Roth IRA Strategy in 2021
https://practicaldermatology.com/topics/practice-management/backdoor-roth-ira-strategy-in-2021/23480/As tax increases may come for high-income earners, we offer an effective step toward tax diversification.The New Normal in Psoriasis Care
https://practicaldermatology.com/columns/clinical-focus-1/the-new-normal-in-psoriasis-care/23436/Lifestyle changes can help psoriasis patients cope with COVID-19.Facing the Impact of Rosacea
https://practicaldermatology.com/columns/clinical-focus-1/facing-the-impact-of-rosacea/23394/New data shed light on the patient experience.How Can I Reduce Irritation from Face Masks?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/how-can-i-reduce-irritation-from-face-masks/19824/Friction from masks can initiate an inflammatory response. Dr. Friedman explains how to reduce and prevent the inflammation with facial moisturizers and other tools.Biologics for Psoriasis: A Status Update
https://practicaldermatology.com/topics/psoriasis/biologics-for-psoriasis-a-status-update/23006/The field has grown substantially from the early 2000s to include now a dozen innovator systemic agents, a host of biosimilars, and soon JAK Inhibitors.